SIVEC BIOTECHNOLOGIES, INC.
Windsor, CO · Founded 2022 · CIK 0002085969 · Biotech · Private
Non-immunogenic engineered bacteria that deliver short hairpin RNA to mucosal cells to trigger RNA interference against influenza virus
sivecbiotechnologies.com →- Grants
- $7.0M
- 7 awards
- Sector median: 1
- Raised
- $3.3M
- 1 Form D · Sep 2025
- 13 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · A versatile transkingdom platform for therapeutic nucleic acid delivery to mucosal epithelial tissues | $293,142 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · A versatile transkingdom platform for therapeutic nucleic acid delivery to mucosal epithelial tissues | $293,142 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform | $1,028,842 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform | $3,048,652 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform | $1,019,722 | |
| Federal grant | Department of Health and Human Services · Phase I · A large-capacity bacterial platform for the production and targeted delivery of gene editing systems | $286,081 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform | $1,000,088 | |
| Private capital raised | Form D · SEC | $3,299,994 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2516 | Prosetta Biosciences Inc. | — | $31M |
| 2517 | Metselex, Incorporated | — | — |
| 2518 | Radionetics Oncology | — | $54M |
| 2519 | SIVEC BIOTECHNOLOGIES, INC. | — | $3.3M |
| 2520 | MOUNTAIN VALLEY MD INC. | — | $18M |
| 2521 | Botanix Pharmaceuticals Ltd. | — | $20M |
| 2522 | Quantum Simulation Technologies, Inc. | — | $7.3M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Richard Freed IIIDirector
- Sibylle HauserDirector
- Lyndsey LinkeDirector · Executive Officer
- Darcy MoraDirector · Executive Officer
- David SherrisDirector
Patents
- Chimeric Invasin Systemapplication
- Bacterial Delivery Of Antibodies, Antibody Derivatives, And Polypeptides To Eukaryotic Cellsapplication
- Chimeric Invasin Systemapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.